- Home
- QSG vs PRTC Comparison
QSG vs PRTC Comparison
Compare QSG & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QSG
- PRTC
- Stock Information
- Founded
- QSG 2019
- PRTC 2015
- Country
- QSG China
- PRTC United States
- Employees
- QSG N/A
- PRTC N/A
- Industry
- QSG Other Consumer Services
- PRTC Biotechnology: Pharmaceutical Preparations
- Sector
- QSG Real Estate
- PRTC Health Care
- Exchange
- QSG Nasdaq
- PRTC Nasdaq
- Market Cap
- QSG 441.6M
- PRTC 388.6M
- IPO Year
- QSG 2023
- PRTC N/A
- Fundamental
- Price
- QSG $9.60
- PRTC $15.39
- Analyst Decision
- QSG Buy
- PRTC Buy
- Analyst Count
- QSG 2
- PRTC 1
- Target Price
- QSG $5.81
- PRTC $45.00
- AVG Volume (30 Days)
- QSG 720.3K
- PRTC 5.0K
- Earning Date
- QSG 09-17-2025
- PRTC 08-28-2025
- Dividend Yield
- QSG 1.90%
- PRTC N/A
- EPS Growth
- QSG 92.28
- PRTC N/A
- EPS
- QSG 1.12
- PRTC 0.20
- Revenue
- QSG $428,283,608.00
- PRTC $6,391,000.00
- Revenue This Year
- QSG N/A
- PRTC N/A
- Revenue Next Year
- QSG N/A
- PRTC N/A
- P/E Ratio
- QSG $10.43
- PRTC $7.29
- Revenue Growth
- QSG N/A
- PRTC 1265.60
- 52 Week Low
- QSG $1.58
- PRTC $13.30
- 52 Week High
- QSG $15.64
- PRTC $24.99
- Technical
- Relative Strength Index (RSI)
- QSG 55.43
- PRTC 34.46
- Support Level
- QSG $8.36
- PRTC $15.75
- Resistance Level
- QSG $8.98
- PRTC $16.75
- Average True Range (ATR)
- QSG 0.93
- PRTC 0.62
- MACD
- QSG 0.29
- PRTC -0.14
- Stochastic Oscillator
- QSG 33.50
- PRTC 0.00
About QSG QuantaSing Group Limited
QuantaSing Group Ltd is a lifestyle solution provider. The company offers engaging, affordable, and accessible online and offline services, as well as consumer products in selected areas that address adult learners. The group has expanded into the pop toys sector and continues to strategically diversify its portfolio by capturing opportunities in consumer sectors while maintaining financial discipline.
About PRTC PureTech Health plc
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.